Canterbury DHB

Context

Summary of Current Indications for SCT at Christchurch

This section gives a broad outline of current recommendations and directs the reader to recent publications. Many factors impact on the final decision to proceed to SCT. They will, to some extent, vary with the individual patient. In addition, recommendations appropriate at any given time may be out of date within a few months.

General guidelines have been published by the American Society for Blood and Transplantation, the European Group for Blood and Marrow Transplantation (EBMT) and the British Society for Blood and Marrow Transplantation (BSBMT):

The American Society of Blood and Marrow Transplantation (ASBMT) in partnership with the US National Marrow Donor Program (NMDP) has produced the following useful resources:

The New Zealand BMT Plan published in 2010 set out nationally agreed guidelines for transplantation.

For disease-specific resources please click on the link below.

In This Section

Acute Myeloid Leukaemia

Acute Lymphoblastic Leukaemia

Burkitt Leukaemia/Lymphoma

Chronic Myeloid Leukaemia

Chronic Lymphocytic Leukaemia

Myeloma

Amyloidosis

Myelodysplasia

Primary myelofibrosis (PMF) and MF secondary to ET/PRV

Aplastic Anaemia

Lymphoma

About this Canterbury DHB document (8144):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 8144